Andrea Nuñez

Ms. Andrea Nuñez


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2011 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JBJudit Barniol
Judit Barniol
RGRoger Gaczkowski
Roger Gaczkowski
EBEliana Vega Barbato
Eliana Vega Barbato
RCRivaldo V da Cunha
Rivaldo V da Cunha
DSDoris Salgado
Doris Salgado
TJThomas Jaenisch
Thomas Jaenisch
In view of the long term discussion on the appropriateness of the dengue classification into dengue fever (DF), dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS), the World Health Organization (WHO) has outlined in its new global dengue guidelines a revised classification into levels of severity: dengue fever with an intermediary group of "dengue fever with warning sings", and severe dengue. The objective of this paper was to compare the two classification systems regarding applicability in clinical practice and surveillance, as well as user-friendliness and acceptance by health staff.

19 March 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
JZJose Victor Zambrana
Jose Victor Zambrana
CSCarlos Saenz
Carlos Saenz
HMHannah E. Maier
Hannah E. Maier
MBMayling Brenes
Mayling Brenes
ANAndrea Nuñez
Andrea Nuñez
ABAngel Balmaseda
Angel Balmaseda
Few data are available on antibody response for some SARS-CoV-2 vaccines, and there is a lack of ability to compare vaccine responses in the same population. This cross-sectional study conducted in Nicaragua examines the SARS-CoV-2 antibody responses in individuals, previously exposed to high infection rates who have received various vaccines. The vaccines under comparison include well-known ones like Pfizer (BNT162b2) and AstraZeneca (ChAdOx1-S), alongside less-studied vaccines including Soberana (Soberana 02), Abdala (CIGB-66), and Sputnik V/Sputnik Light. Overall, 3195 individuals participated, with 2862 vaccinated and 333 unvaccinated. We found that 95% of the unvaccinated were seropositive, with much lower titers than the vaccinated. Among the vaccinated, we found that Soberana recipients mounted the highest anti-spike response (mean difference (MD) = 36,498.8 [20,312.2, 52,685.5]), followed by Abdala (MD = 25,889.9 [10,884.1, 40,895.7]), BNT162b2 (MD = 12,967.2 [7543.7, 18,390.8]) and Sputnik with AstraZeneca as the reference group, adjusting for age, sex, vaccine status, days after last dose, and self-reported COVID-19. In addition, we found that subjects with complete vaccination series had higher antibody magnitude than those with incomplete series. Overall, we found no evidence of waning in the antibody magnitude across vaccines. Our study supports the conclusion that populations with high infection rates still benefit substantially from vaccination.